Drug Update · Infectious Disease

FDA Expands AREXVY to Adults 18–59 at Increased RSV Risk

August 23, 2026

Expanded indication

Individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV [1]

Original indication retained

Individuals 60 years of age and older [1]

Pivotal adult efficacy (reported)

82.6% reduction in RSV-associated LRTD; 94.1% reduction in severe RSV-associated LRTD versus placebo in main adult trial [2]

Approximate trial enrollment cited

Approximately 12,500 participants received AREXVY and approximately 12,500 received placebo in the cited adult dataset [2]

Recent FDA action date on AREXVY page

Approval Letter - AREXVY dated June 29, 2026 listed on FDA product page [1]

Clinical Perspective

This update is directly relevant to infectious disease physicians, primary care clinicians, and immunization providers caring for adults, including adults aged 18 through 59 who meet FDA criteria as being “at increased risk” for RSV-associated lower respiratory tract disease. The FDA’s expanded labeling makes AREXVY an FDA‑labeled preventive vaccine option for older adults and for adults 18–59 years of age who are at increased risk for LRTD caused by RSV; earlier pivotal adult data reported large relative risk reductions for RSV‑associated LRTD and severe LRTD in the randomized trial in adults 60 years and older. How clinicians will operationalize the term “at increased risk” for adults 18–59 in practice (specific qualifying conditions, immunocompromising states, or cardiopulmonary diagnoses) will require review of the full FDA approval materials and the current prescribing information.

Dr. Simran Kohli, MBBS, MD (General Medicine), DM (Infectious Diseases) · Infectious Diseases

The U.S. Food and Drug Administration has expanded the labeled indication for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) to include individuals 18 through 59 years of age who are at increased risk for lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), with an approval document listed June 29, 2026 on the FDA AREXVY regulatory page ^[1]. The vaccine program’s pivotal adult data previously showed reduction in RSV-associated LRTD by 82.6% and in severe RSV-associated LRTD by 94.1% versus placebo in the main randomized trial in adults 60 years of age and older ^[2].

Clinical Context

AREXVY is listed by the FDA under the proper name Respiratory Syncytial Virus Vaccine, Adjuvanted and is manufactured by GlaxoSmithKline Biologicals SA; the FDA product page and approval documents are posted on the agency’s website ^[1]. The AREXVY label on the FDA site states the vaccine is indicated to prevent LRTD caused by RSV in two populations: individuals 60 years of age and older, and individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV ^[1]. In the agency’s original announcement for the first U.S. approval, the FDA described an ongoing randomized, placebo-controlled clinical study in older adults and reported that one-season data showed a substantial reduction in RSV-associated LRTD and in severe LRTD compared with placebo ^[2]. The FDA page also identifies a required Guillain-Barré syndrome warning added for RSV vaccines Abrysvo and Arexvy in January 2025 ^[1].

Key Findings

The main randomized, placebo-controlled clinical study in adults 60 years of age and older showed that AREXVY reduced the risk of developing RSV-associated lower respiratory tract disease by 82.6% versus placebo in the first RSV season of analysis ^[2].
In the same study subset, AREXVY reduced the risk of developing severe RSV-associated lower respiratory tract disease by 94.1% versus placebo ^[2].
Approximately 12,500 participants received AREXVY and approximately 12,500 received placebo in the clinical program dataset cited by the FDA press announcement describing the pivotal adult data ^[2].

These efficacy figures derive from the randomized trial data reported by the FDA at initial approval and cited on the agency’s public materials; the FDA’s AREXVY product page lists the updated indication that includes adults 18 through 59 years of age who are at increased risk for RSV LRTD ^[1]^[2].

Safety & Tolerability

The most commonly reported adverse reactions among trial participants who received AREXVY included injection site pain, fatigue, muscle pain, headache, and joint stiffness/pain ^[2].
Atrial fibrillation within 30 days of vaccination was reported in 10 participants who received AREXVY and in 4 participants who received placebo in the clinical dataset described by the FDA ^[2].
The FDA requires a Guillain-Barré syndrome (GBS) warning in the prescribing information for RSV vaccines Abrysvo and Arexvy (January 7, 2025) as noted on the AREXVY FDA page ^[1].

Study Design

The FDA’s public materials describe the pivotal adult clinical program as an ongoing randomized, placebo-controlled trial conducted in the U.S. and internationally in individuals 60 years of age and older; approximately 12,500 participants received AREXVY and approximately 12,500 received placebo in the dataset cited by the agency ^[2]. Participants are to remain in the study through three RSV seasons to assess duration of effectiveness and repeat vaccination; the FDA product page lists multiple approval letters including an approval document dated June 29, 2026 corresponding to recent regulatory actions for AREXVY ^[1]^[2]. Specific trial name identifiers and subgroup efficacy data for the newly included 18–59 at-risk population were not detailed in the FDA summary materials available on the public pages ^[1]^[2].

FAQ

Q1 What is AREXVY approved for?

AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is approved by the FDA for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in two populations: individuals 60 years of age and older; and individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV, as stated on the FDA AREXVY product page and related approval documents.

Q2 How does AREXVY work?

[Information] was not available in the provided source excerpts.

Q3 What is the recommended dose of AREXVY?

[Information] was not available in the provided source excerpts. Clinicians should consult current prescribing information for full dosing guidance.

Q4 What are the most common side effects?

The FDA-reported clinical dataset cited common adverse reactions including injection site pain, fatigue, muscle pain, headache, and joint stiffness/pain among participants who received AREXVY. In the same dataset, atrial fibrillation within 30 days of vaccination occurred in 10 vaccine recipients and 4 placebo recipients. The FDA also requires a Guillain-Barré syndrome warning in the prescribing information for AREXVY and Abrysvo, per the agency’s safety communications.

Clinicians should consult current prescribing information for full dosing guidance.

FDA Expands AREXVY to Adults 18–59 at Increased RSV Risk

Direct Clinical Takeaway & Evidence Summary

FDA Expands AREXVY to Adults 18–59 at Increased RSV Risk

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Infectious Disease in your inbox.

Related Clinical Updates

FDA Approves zoliflodacin for Uncomplicated Urogenital Gonorrhea: 90.9% Microbiologic Cure

FDA Approves doravirine/islatravir for Virologically Suppressed HIV‑1: 1% ≥50 copies/mL

REVIVE: Fluvoxamine Reduces Fatigue Severity (−0.43 FSS) vs Placebo

Verified HCP Portal